Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase II Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Vascularization of Liver Metastases of Metastatic Colorectal Cancer: Proof of Concept Study

Next Previous
Trial Profile

Phase II Study Evaluating the Influence of LV5FU2 Bevacizumab Plus Anakinra Association on Vascularization of Liver Metastases of Metastatic Colorectal Cancer: Proof of Concept Study

Status: Completed
Phase of Trial: Phase II

Latest Information Update: 06 Nov 2021

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Anakinra (Primary) ; Bevacizumab; Cisplatin; Fluorouracil; Folinic acid
  • Indications Adenocarcinoma; Colorectal cancer
  • Focus Proof of concept; Therapeutic Use
  • Acronyms IRAFU

Most Recent Events

  • 08 Aug 2018 Status changed from active, no longer recruiting to completed.
  • 05 Jun 2018 Results (n=32) assessing efficacy of anakinra in combination with bevacizumab and fluorouracil, folinic acid and cisplatin (FV5FU2), were presented at the 54th Annual Meeting of the American Society of Clinical Oncology.
  • 19 Jun 2017 Status changed from recruiting to active, no longer recruiting.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top